Literature DB >> 7881692

Approaches to the treatment of pulmonary fibrosis.

G W Hunninghake1, A R Kalica.   

Abstract

There was a general consensus at the workshop that pulmonary fibrosis is a highly lethal lung disorder and that current therapies for this disease have little effect on the natural history of the disease. There was also broad consensus that much has been learned about the pathogenesis of this disease in recent years and this information can be used to direct new therapies for this disease. As a complement to the findings from studies on pulmonary fibrosis itself, there has also been significant development of new therapies for other disorders that might be useful in treating patients with pulmonary fibrosis. The following is a list of some of the issues and recommendations that were generated from this workshop.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7881692     DOI: 10.1164/ajrccm.151.3.7881692

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  9 in total

1.  Induction of fibroblast apoptosis by anti-CD44 antibody: implications for the treatment of fibroproliferative lung disease.

Authors:  C Henke; P Bitterman; U Roongta; D Ingbar; V Polunovsky
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

Review 2.  Recognition and treatment of idiopathic pulmonary fibrosis.

Authors:  L P Nicod
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

3.  Prolidase could act as a diagnosis and treatment mediator in lung fibrosis.

Authors:  Ibrahim Türkbeyler; Tuncer Demir; Yavuz Pehlivan; Davut Sinan Kaplan; Ali Osman Ceribasi; Mustafa Orkmez; Nurten Aksoy; Seyithan Taysi; Bunyamin Kisacik; Ahmet Mesut Onat
Journal:  Inflammation       Date:  2012-10       Impact factor: 4.092

4.  Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IFP)/usual interstitial pneumonia (UIP).

Authors:  J V Barbas-Filho; M A Ferreira; A Sesso; R A Kairalla; C R Carvalho; V L Capelozzi
Journal:  J Clin Pathol       Date:  2001-02       Impact factor: 3.411

5.  Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts.

Authors:  D W Mapel; W C Hunt; R Utton; K B Baumgartner; J M Samet; D B Coultas
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

Review 6.  Determinants of mortality in systemic sclerosis: a focused review.

Authors:  Dilli Ram Poudel; Divya Jayakumar; Abhijeet Danve; Shiv Tej Sehra; Chris T Derk
Journal:  Rheumatol Int       Date:  2017-11-07       Impact factor: 2.631

7.  An HSV-TK transgenic mouse model to evaluate elimination of fibroblasts for fibrosis therapy.

Authors:  Bin Tian; Lei Han; Jill Kleidon; Craig Henke
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

8.  Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis.

Authors:  Yi-Wei Tang; Joyce E Johnson; Philip J Browning; Roberto A Cruz-Gervis; Angela Davis; Barney S Graham; Kenneth L Brigham; John A Oates; James E Loyd; Arlene A Stecenko
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

9.  Potential role of the inflammasome-derived inflammatory cytokines in pulmonary fibrosis.

Authors:  Rupa Biswas; Melisa Bunderson-Schelvan; Andrij Holian
Journal:  Pulm Med       Date:  2011-06-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.